Trial · NCT03733535
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
NCT03733535, Not applicable, Active not recruiting, Dr. Grace Parraga
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI. Trials, record NCT03733535. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03733535
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
- NCT number
- NCT03733535
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 29 participants, actual
- Lead sponsor
- Dr. Grace Parraga
- Conditions
- Asthma; Eosinophilic
- Interventions
- Benralizumab, 129 Xenon
- First posted
- 2018-11-07
- Last updated
- 2025-08-11
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline airway function measured using 129-Xenon MRI ventilation defect percent | Day 0 and 28 | Changes in VDP |
| Secondary | Change from baseline airway function measured using 129-Xenon MRI ventilation defect percent | Day 0, 14 and 112 | Changes in VDP |
| Secondary | Change from baseline blood eosinophils | Day 0, 14 and 112 | |
| Secondary | Change from baseline forced expiration volume in one second | Day 0, 14, 28 and 112 | Indicator of pulmonary function |
| Secondary | Change from baseline forced vital capacity | Day 0, 14, 28 and 112 | Indicator of pulmonary function |
| Secondary | Change from baseline lung volumes | Day 0, 14, 28 and 112 | Indicator of pulmonary function |
| Secondary | Change from baseline airways resistance | Day 0, 14, 28 and 112 | Indicator of pulmonary function and inflammation |
| Secondary | Change from baseline forced oscillation technique | Day 0, 14, 28 and 112 | Indicator of pulmonary function and inflammation |
| Secondary | Change from baseline lung clearance index | Day 0, 14, 28 and 112 | Indicator of pulmonary function |
| Secondary | Change from baseline fraction exhaled nitric oxide | Day 0, 14, 28 and 112 | Indicator of pulmonary function and inflammation |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03733535
GET https://conductscience.org/api/trials/v1/NCT03733535/registered?page=2